关键词: 黄皮新肉桂酰胺B, 无可见有害作用水平, 降血脂

Abstract: Objective: To explore the hypolipidemic activity of lansiumamide B (LB) based on the high-fat-diet model in C57BL/6 mice for the first time. Methods: The C57BL/6 mice were intragastric administrated with LB to explore the NOAEL (no observed adverse effect level) of LB. The concentration of the lipid-lowering experiments were set on the basis of the NOAEL of LB. After establishing the high-fat model, mice were intragastric administered for 4 weeks, then evaluated via body weight, biochemical indexes, insulin resistance, major organs injury and skeletal development. Results: Through the acute oral toxicity experiment results, the NOAEL of LB on C57BL/6 mice was 2 g/kg·bw (body weight). The results of the hypolipidemic experiment suggested that LB significantly reduced the body weight of mice. Among of these results, compared to HFD (high-fat-diet model group), the body weight of HLB (80 mg/kg drug group) reduced 15.51%, the Lee's index fell 3.25 %, HDL-C (High Density Lipid-Cholesterol) increased by 38.04%, the SOD (Superoxide Dismutase), GSH-Px (glutathione peroxidase) and CAT (Catalase) enzymes increased by 41.86%, 41.95% and 105.50% respectively. Conclusion: The NOAEL of LB is 2 g/kg·bw and the concentration within the NOAEL has observably hypolipidemic activity in mice.

Key words: lansiumamide B, no observed adverse effect level, hypolipidemic